Search

Your search keyword '"Thijs, Judith"' showing total 236 results
Start Over Author "Thijs, Judith"
236 results on '"Thijs, Judith"'

5. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Author

Ariëns, Lieneke F.M., van der Schaft, Jorien, Spekhorst, Lotte S., Bakker, Daphne S., Romeijn, Geertruida L.E., Kouwenhoven, Tessa A., Kamsteeg, Marijke, Voorberg, Angelique N., Oosting, Albert J., de Ridder, Ilona, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L., Schuttelaar, Marie L.A., and de Bruin-Weller, Marjolein S.

Published
2021
Full Text
View/download PDF

7. Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile.

Author

Achten, Roselie, van Luijk, Chantal, Thijs, Judith, Drylewicz, Julia, Delemarre, Eveline, Nierkens, Stefan, Bakker, Daphne, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein, de Boer, Joke, and Kuiper, Jonas

Subjects
AQUEOUS humor, ACADEMIC medical centers, MACULAR edema, ATOPIC dermatitis, UVEITIS, IRIDOCYCLITIS
Abstract

Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab treatment and to compare the proteomic profile of aqueous humor (AqH) of dupilumab-associated uveitis (n=3/5 available samples) with non-infectious uveitis (n=27) and cataract controls (n=11). Included patients were treated at the University Medical Center Utrecht (the Netherlands). Active dupilumab-associated uveitis complicated by serous detachment, cystoid macular edema, or secondary glaucoma developed within a median of 6.0 months (interquartile range 2.3–16.5 months) after starting dupilumab. Uveitis resolved after discontinuation of dupilumab and/or treatment with local or systemic corticosteroids. Proteomic profiling of AqH revealed that the molecular profile of dupilumab-associated uveitis resembled that of non-infectious uveitis. In conclusion, dupilumab-associated uveitis is a severe adverse event of dupilumab therapy, requiring urgent referral to an ophthalmologist. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy

Author

Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), MS Dermatologie/Allergologie, CTI Research, Apotheek Opleiding, Apotheek KF TDM, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein, Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), MS Dermatologie/Allergologie, CTI Research, Apotheek Opleiding, Apotheek KF TDM, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein

Published
2024

9. Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile

Author

MS Dermatologie/Allergologie, Infection & Immunity, MS Oogheelkunde, Other research (not in main researchprogram), CTI Computational Immunology Core, CTI Bont, CTI Research, Cancer, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Achten, Roselie, van Luijk, Chantal, Thijs, Judith, Drylewicz, Julia, Delemarre, Eveline, Nierkens, Stefan, Bakker, Daphne, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein, de Boer, Joke, Kuiper, Jonas, MS Dermatologie/Allergologie, Infection & Immunity, MS Oogheelkunde, Other research (not in main researchprogram), CTI Computational Immunology Core, CTI Bont, CTI Research, Cancer, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Achten, Roselie, van Luijk, Chantal, Thijs, Judith, Drylewicz, Julia, Delemarre, Eveline, Nierkens, Stefan, Bakker, Daphne, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein, de Boer, Joke, and Kuiper, Jonas

Published
2024

11. Ocular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy.

Author

Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, and de Bruin‐Weller, Marjolein

Subjects
*ATOPIC dermatitis, *BIOTHERAPY, *ECZEMA, *DUPILUMAB, *SKIN diseases, *MEDICAL personnel
Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate‐to‐severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate‐to‐severe AD already have characteristics of OSD before starting targeted treatment. Remarkably, not all AD patients with OSD report ocular symptoms. OSD in AD is associated with less conjunctival goblet cells (GC) compared to healthy controls. In addition, OSD severity in AD patients is associated with high AD activity, the presence of eyelid and/or facial eczema, and high levels of AD‐related severity biomarkers in tear fluid. The second part of this review highlights that pre‐existing ocular pathology (e.g. in combination with the use of ophthalmic medication or eyelid eczema) may be associated with the development of dupilumab‐associated ocular surface disease (DAOSD). During dupilumab treatment, DAOSD (which can be new‐onset OSD or worsening of pre‐existing OSD) is observed in approximately one‐third of the dupilumab‐treated AD patients. Anti‐inflammatory ophthalmic treatment improves DAOSD, and dose reduction of dupilumab may also be an effective treatment option. The pathomechanism of DAOSD is still not fully elucidated. In a prospective study low, but stable conjunctival GC numbers were observed in moderate‐to‐severe AD patients, before and during dupilumab treatment. However, the Mucin 5 AC (MUC5AC) expression of GCs decreased during dupilumab treatment, suggesting an impairment of the GC function by dupilumab treatment. In addition, higher dupilumab tear fluid levels were found in dupilumab‐treated AD patients with moderate‐to‐severe OSD compared to patients with no or mild OSD, whereas the dupilumab serum levels are similar. Clinicians should be aware of the frequent occurrence of OSD in moderate‐to‐severe AD patients, and a low‐threshold referral to an ophthalmologist is recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin-Weller, Marjolein, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

15. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Achten, Roselie, Dekkers, Coco, Bakker, Daphne, van Luijk, Chantal, de Graaf, Marlies, van Wijk, Femke, de Boer, Joke, de Bruin-Weller, Marjolein, Thijs, Judith, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Achten, Roselie, Dekkers, Coco, Bakker, Daphne, van Luijk, Chantal, de Graaf, Marlies, van Wijk, Femke, de Boer, Joke, de Bruin-Weller, Marjolein, and Thijs, Judith

Published
2023

16. Biomarkers in atopic dermatitis

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Bakker, Daphne, de Bruin-Weller, Marjolein, Drylewicz, Julia, van Wijk, Femke, Thijs, Judith, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CTI, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Bakker, Daphne, de Bruin-Weller, Marjolein, Drylewicz, Julia, van Wijk, Femke, and Thijs, Judith

Published
2023

17. High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Apotheek Klinische Farmacie, Apotheek KF TDM, CTI Research, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, van Luin, Matthijs, El Amrani, Mohsin, Knol, Edward, Delemarre, Eveline, Jager, Constance den Hartog, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Apotheek Klinische Farmacie, Apotheek KF TDM, CTI Research, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, van Luin, Matthijs, El Amrani, Mohsin, Knol, Edward, Delemarre, Eveline, Jager, Constance den Hartog, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

18. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Research, CTI Bont, CTI Van Wijk, Child Health, Achten, Roselie, Thijs, Judith, van Luijk, Chantal, Knol, Edward, Delemarre, Eveline, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Research, CTI Bont, CTI Van Wijk, Child Health, Achten, Roselie, Thijs, Judith, van Luijk, Chantal, Knol, Edward, Delemarre, Eveline, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

19. Dupilumab‐associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Author

Achten, Roselie, primary, Thijs, Judith, additional, van der Wal, Marlot, additional, van Luijk, Chantal, additional, de Graaf, Marlies, additional, Bakker, Daphne, additional, de Boer, Joke, additional, van Wijk, Femke, additional, and de Bruin‐Weller, Marjolein, additional

Published
2023
Full Text
View/download PDF

22. Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile

Author

Achten, Roselie, primary, van Luijk, Chantal, additional, Thijs, Judith, additional, Drylewicz, Julia, additional, Delemarre, Eveline, additional, Nierkens, Stefan, additional, Bakker, Daphne, additional, van Wijk, Femke, additional, de Graaf, Marlies, additional, de Bruin-Weller, Marjolein, additional, de Boer, Joke, additional, and Kuiper, Jonas, additional

Published
2023
Full Text
View/download PDF

23. High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Author

Achten, Roselie, primary, Thijs, Judith, additional, van der Wal, Marlot, additional, van Luijk, Chantal, additional, van Luin, Matthijs, additional, el Amrani, Mohsin, additional, Knol, Edward, additional, Delemarre, Eveline, additional, Jager, Constance den Hartog, additional, de Graaf, Marlies, additional, Bakker, Daphne, additional, de Boer, Joke, additional, van Wijk, Femke, additional, and de Bruin‐Weller, Marjolein, additional

Published
2023
Full Text
View/download PDF

25. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis

Author

Spekhorst, Lotte S., primary, de Graaf, Marlies, additional, Loeff, Floris, additional, Zuithoff, Nicolaas P. A., additional, Bakker, Daphne, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Achten, Roselie, additional, van Wijk, Femke, additional, Rispens, Theo, additional, and de Bruin-Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

29. ESDR126 - Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients

Author

Spekhorst, Lotte, primary, de Graaf, Marlies, primary, Loeff, Floris, primary, Zuithoff, Nicolaas, primary, Bakker, Daphne, primary, Boesjes, Celeste, primary, Thijs, Judith, primary, Achten, Roselie, primary, van Wijk, Femke, primary, Rispens, Theo, primary, and de Bruin-Weller, Marjolein, primary

Published
2022
Full Text
View/download PDF

30. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

Spekhorst, Lotte S., primary, Bakker, Daphne, additional, Drylewicz, Julia, additional, Rispens, Theo, additional, Loeff, Floris, additional, Boesjes, Celeste M., additional, Thijs, Judith, additional, Romeijn, Geertruida L. E., additional, Loman, Laura, additional, Schuttelaar, Marie‐Louise, additional, van Wijk, Femke, additional, de Graaf, Marlies, additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

31. Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis: A Prospective Clinical Cohort Study from the BioDay Registry

Author

MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, De Bruin-Weller, Marjolein S., MS Dermatologie/Allergologie, Infection & Immunity, Biostatistiek Onderzoek, Other research (not in main researchprogram), Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Spekhorst, Lotte S., De Graaf, Marlies, Loeff, Floris, Zuithoff, Nicolaas P.A., Bakker, Daphne, Boesjes, Celeste M., Thijs, Judith, Achten, Roselie, Van Wijk, Femke, Rispens, Theo, and De Bruin-Weller, Marjolein S.

Published
2022

32. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Biostatistiek Onderzoek, Julius Centrum, Achten, Roselie E, Bakker, Daphne S, van Luijk, Chantal M, van der Wal, M Marlot, de Graaf, Marlies, van Wijk, Femke, Zuithoff, Nicolaas P A, van der Rijst, Lisa P, Boesjes, Celeste M, Thijs, Judith L, de Boer, Joke H, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Biostatistiek Onderzoek, Julius Centrum, Achten, Roselie E, Bakker, Daphne S, van Luijk, Chantal M, van der Wal, M Marlot, de Graaf, Marlies, van Wijk, Femke, Zuithoff, Nicolaas P A, van der Rijst, Lisa P, Boesjes, Celeste M, Thijs, Judith L, de Boer, Joke H, and de Bruin-Weller, Marjolein S

Published
2022

33. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Biostatistiek Onderzoek, Achten, Roselie E, Van Luijk, Chantal, Van der Rijst, Lisa, Bakker, Daphne, Spekhorst, Lotte, Zuithoff, Nicolaas, Schuttelaar, Marie, Romeijn, Geertruida, Voorberg, Angelique, Kamsteeg, Marijke, Haeck, Inge, De Graaf, Marlies, Thijs, Judith, De Boer, Joke, De Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, MS Oogheelkunde, Other research (not in main researchprogram), Unit Opleiding Dermatologie, Biostatistiek Onderzoek, Achten, Roselie E, Van Luijk, Chantal, Van der Rijst, Lisa, Bakker, Daphne, Spekhorst, Lotte, Zuithoff, Nicolaas, Schuttelaar, Marie, Romeijn, Geertruida, Voorberg, Angelique, Kamsteeg, Marijke, Haeck, Inge, De Graaf, Marlies, Thijs, Judith, De Boer, Joke, and De Bruin-Weller, Marjolein

Published
2022

34. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Computational Immunology Core, CTI Van Wijk, Child Health, Spekhorst, Lotte S, Bakker, Daphne, Drylewicz, Julia, Rispens, Theo, Loeff, Floris, Boesjes, Celeste M, Thijs, Judith, Romeijn, Geertruida L E, Loman, Laura, Schuttelaar, Marie-Louise, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein S

Published
2022

35. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts

Author

CTI Van Loosdregt, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Reumat./Klin. Immunologie, Lab Reumatologie/Klinische Immunologie, CTI CFF, CTI Van Wijk, Unit Opleiding Dermatologie, MS Dermatologie/Allergologie, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Angiolilli, Chiara, Leijten, Emmerik F A, Bekker, Cornelis P J, Eeftink, Ella, Giovannone, Barbara, Nordkamp, Michel Olde, van der Wal, Marlot, Thijs, Judith L, Vastert, Sebastiaan J, van Wijk, Femke, Radstake, Timothy R D J, van Loosdregt, Jorg, CTI Van Loosdregt, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Reumat./Klin. Immunologie, Lab Reumatologie/Klinische Immunologie, CTI CFF, CTI Van Wijk, Unit Opleiding Dermatologie, MS Dermatologie/Allergologie, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Angiolilli, Chiara, Leijten, Emmerik F A, Bekker, Cornelis P J, Eeftink, Ella, Giovannone, Barbara, Nordkamp, Michel Olde, van der Wal, Marlot, Thijs, Judith L, Vastert, Sebastiaan J, van Wijk, Femke, Radstake, Timothy R D J, and van Loosdregt, Jorg

Published
2022

36. Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI UDAIR, CTI Van Wijk, Child Health, CTI Computational Immunology Core, Bakker, Daphne S, Graaf, Marlies de, Nierkens, Stefan, Delemarre, Eveline M, Knol, Edward, van Wijk, Femke, de Bruin-Weller, Marjolein S, Drylewicz, Julia, Thijs, Judith L, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI UDAIR, CTI Van Wijk, Child Health, CTI Computational Immunology Core, Bakker, Daphne S, Graaf, Marlies de, Nierkens, Stefan, Delemarre, Eveline M, Knol, Edward, van Wijk, Femke, de Bruin-Weller, Marjolein S, Drylewicz, Julia, and Thijs, Judith L

Published
2022

37. Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Author

Achten, Roselie E., primary, Bakker, Daphne S., additional, van Luijk, Chantal M., additional, van der Wal, Marlot, additional, de Graaf, Marlies, additional, van Wijk, Femke, additional, Zuithoff, Nicolaas P.A., additional, van der Rijst, Lisa P., additional, Boesjes, Celeste M., additional, Thijs, Judith L., additional, de Boer, Joke H., additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

38. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

Author

Achten, Roselie E., primary, Van Luijk, Chantal, additional, Van der Rijst, Lisa, additional, Bakker, Daphne, additional, Spekhorst, Lotte, additional, Zuithoff, Nicolaas, additional, Schuttelaar, Marie, additional, Romeijn, Geertruida, additional, Voorberg, Angelique, additional, Kamsteeg, Marijke, additional, Haeck, Inge, additional, De Graaf, Marlies, additional, Thijs, Judith, additional, De Boer, Joke, additional, and De Bruin-Weller, Marjolein, additional

Published
2022
Full Text
View/download PDF

40. Biomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopic dermatitis patients.

Author

Achten, Roselie, Thijs, Judith, van Luijk, Chantal, Knol, Edward, Delemarre, Eveline, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin‐Weller, Marjolein

Subjects
*ATOPIC dermatitis, *ROSACEA, *BIOMARKERS, *CYTOTOXIC T cells
Abstract

Due to the impaired epithelial barrier function in eyes of AD patients, as suggested by Yokoi et al.,[7] the AD-related severity tear fluid biomarkers might be increased in AD patients with more severe OSD and play a role in the local barrier disruption. Although not all statistically significant, IL-22, TARC and periostin tear fluid levels remained higher in patients with moderate-to-severe OSD compared to patients with no or mild OSD during dupilumab treatment (Figure 1B). However, moderate-to-severe OSD patients remained to have slightly higher tear fluid levels of TARC, IL-22 and periostin compared to patients with no or mild OSD. This study, funded by dupilumab's manufacturer, measured tear fluid biomarker levels from dupilumab-treated atopic dermatitis (AD) patients. [Extracted from the article]

Published
2023
Full Text
View/download PDF

41. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Author

Ariëns, Lieneke F.M., primary, Bakker, Daphne S., additional, Spekhorst, Lotte S., additional, Van der Schaft, Jorien, additional, Thijs, Judith L., additional, Haeck, Inge, additional, Flinterman, Annebeth E., additional, Kamsteeg, Marijke, additional, Schuttelaar, Marie L.A., additional, and De Bruin-Weller, Marjolein S., additional

Published
2021
Full Text
View/download PDF

42. Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Author

Bakker, Daphne S., primary, ter Linde, José J. M., additional, Amini, Mojtaba M., additional, Ariëns, Lieneke F. M., additional, van Luijk, Chantal M., additional, de Bruin‐Weller, Marjolein S., additional, Thijs, Judith L., additional, Vercoulen, Yvonne, additional, and van Wijk, Femke, additional

Published
2021
Full Text
View/download PDF

43. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis

Author

Bakker, Daphne S; https://orcid.org/0000-0002-0193-5794, van der Wal, Maria M; https://orcid.org/0000-0003-4554-9059, Heeb, Lukas E M; https://orcid.org/0000-0002-2696-0873, Giovannone, Barbara; https://orcid.org/0000-0003-3143-1922, Asamoah, Mindy; https://orcid.org/0000-0003-4308-9415, Delemarre, Eveline M; https://orcid.org/0000-0002-4310-0998, Drylewicz, Julia; https://orcid.org/0000-0002-9434-8459, Nierkens, Stefan; https://orcid.org/0000-0003-3406-817X, Boyman, Onur; https://orcid.org/0000-0001-8279-5545, de Bruin-Weller, Marjolein S; https://orcid.org/0000-0002-1249-6993, Thijs, Judith L; https://orcid.org/0000-0003-2753-5235, van Wijk, Femke; https://orcid.org/0000-0001-8343-1356, Bakker, Daphne S; https://orcid.org/0000-0002-0193-5794, van der Wal, Maria M; https://orcid.org/0000-0003-4554-9059, Heeb, Lukas E M; https://orcid.org/0000-0002-2696-0873, Giovannone, Barbara; https://orcid.org/0000-0003-3143-1922, Asamoah, Mindy; https://orcid.org/0000-0003-4308-9415, Delemarre, Eveline M; https://orcid.org/0000-0002-4310-0998, Drylewicz, Julia; https://orcid.org/0000-0002-9434-8459, Nierkens, Stefan; https://orcid.org/0000-0003-3406-817X, Boyman, Onur; https://orcid.org/0000-0001-8279-5545, de Bruin-Weller, Marjolein S; https://orcid.org/0000-0002-1249-6993, Thijs, Judith L; https://orcid.org/0000-0003-2753-5235, and van Wijk, Femke; https://orcid.org/0000-0001-8343-1356

Published
2021

44. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Author

CTI Luminex, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CMM Groep Vercoulen, MS Oogheelkunde, Other research (not in main researchprogram), Cancer, CTI Van Wijk, Child Health, Bakker, Daphne S., ter Linde, José J.M., Amini, Mojtaba M., Ariëns, Lieneke F.M., van Luijk, Chantal M., de Bruin-Weller, Marjolein S., Thijs, Judith L., Vercoulen, Yvonne, van Wijk, Femke, CTI Luminex, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, CMM Groep Vercoulen, MS Oogheelkunde, Other research (not in main researchprogram), Cancer, CTI Van Wijk, Child Health, Bakker, Daphne S., ter Linde, José J.M., Amini, Mojtaba M., Ariëns, Lieneke F.M., van Luijk, Chantal M., de Bruin-Weller, Marjolein S., Thijs, Judith L., Vercoulen, Yvonne, and van Wijk, Femke

Published
2021

45. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), Achten, Roselie, Bakker, Daphne, Ariens, Lieneke, Lans, Amanda, Thijs, Judith, van der Schaft, Jorien, de Boer, Joke, Balak, Deepak, de Graaf, Marlies, van Luijk, Chantal, de Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), Achten, Roselie, Bakker, Daphne, Ariens, Lieneke, Lans, Amanda, Thijs, Judith, van der Schaft, Jorien, de Boer, Joke, Balak, Deepak, de Graaf, Marlies, van Luijk, Chantal, and de Bruin-Weller, Marjolein

Published
2021

46. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Author

MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, Ariëns, Lieneke Fm, van der Schaft, Jorien, Spekhorst, Lotte S, Bakker, Daphne S, Romeijn, Geertruida L E, Kouwenhoven, Tessa A, Kamsteeg, Marijke, Voorberg, Angelique N, Oosting, Albert J, Ridder, Ilona de, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L, Schuttelaar, Marie LA, de Bruin-Weller, Marjolein S, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, Infection & Immunity, Ariëns, Lieneke Fm, van der Schaft, Jorien, Spekhorst, Lotte S, Bakker, Daphne S, Romeijn, Geertruida L E, Kouwenhoven, Tessa A, Kamsteeg, Marijke, Voorberg, Angelique N, Oosting, Albert J, Ridder, Ilona de, Sloeserwij, Annemieke, Haeck, Inge, Thijs, Judith L, Schuttelaar, Marie LA, and de Bruin-Weller, Marjolein S

Published
2021

47. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers

Author

MS Dermatologie/Allergologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI, Lab Dermatologie/Allergologie, CTI UDAIR, CTI Van Wijk, Child Health, CTI Borghans, Bakker, Daphne S, Nierkens, Stefan, Knol, Edward F, Giovannone, Barbara, Delemarre, Eveline M, van der Schaft, Jorien, van Wijk, Femke, de Bruin-Weller, Marjolein S, Drylewicz, Julia, Thijs, Judith L, MS Dermatologie/Allergologie, Infection & Immunity, CDL Patiëntenzorg MI, CTI Research, Cancer, CTI, Lab Dermatologie/Allergologie, CTI UDAIR, CTI Van Wijk, Child Health, CTI Borghans, Bakker, Daphne S, Nierkens, Stefan, Knol, Edward F, Giovannone, Barbara, Delemarre, Eveline M, van der Schaft, Jorien, van Wijk, Femke, de Bruin-Weller, Marjolein S, Drylewicz, Julia, and Thijs, Judith L

Published
2021

48. EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Author

Bakker, Daphne S., primary, Ariens, Lieneke F. M., additional, Giovannone, Barbara, additional, Hijnen, DirkJan, additional, Delemarre, Eveline M., additional, Knol, Edward, additional, Nierkens, Stefan, additional, Bruin‐Weller, Marjolein S., additional, Thijs, Judith L., additional, and Drylewicz, Julia, additional

Published
2020
Full Text
View/download PDF

49. BioDay Registry: Prospective, observational data collection regarding the use of new systemic treatment options in patients with atopic diseases in daily practice (Preprint)

Author

BioDay Registry, Jorien, primary, Ariens, Lieneke, additional, Spekhorst, Lotte, additional, Kummeling, Ischa, additional, Thijs, Judith, additional, Bakker, Daphne, additional, de Ridder, Ilona, additional, Sloeserwij, Annemieke, additional, de Graaf, Marlies, additional, Romeijn, Margreet, additional, Voorberg, Angelique, additional, Kamsteeg, Marijke, additional, Schuttelaar, Marie-Louise, additional, and de Bruin-Weller, Marjolein, additional

Published
2020
Full Text
View/download PDF

50. Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Author

Spekhorst, Lotte S., primary, Ariëns, Lieneke F.M., additional, van der Schaft, Jorien, additional, Bakker, Daphne S, additional, Kamsteeg, Marijke, additional, Oosting, Albert J., additional, de Ridder, Ilona, additional, Sloeserwij, Annemiek, additional, Romeijn, Geertruida L.E., additional, de Graaf, Marlies, additional, Haeck, Inge, additional, Thijs, Judith L., additional, Schuttelaar, Marie L.A., additional, and de Bruin‐Weller, Marjolein S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results